A new study has revealed that platelet-derived growth factor-BB (PDGF-BB) could be a promising treatment for Parkinson's disease.
Researchers found that behavioral, tissue and biochemical changes in experimental models of Parkinson's disease in rodents could be counteracted by infusion of PDGF-BB which could offer an alternative strategy to restore function in PD.
"In animal models of nigrostriatal injury, a two weeks treatment with platelet-derived growth factor-BB resulted in long-lasting restoration of striatal dopamine transporter binding sites and expression of nigral tyrosine hydroxylase," said Anders Haegerstrand, Chief Scientific Officer, NeuroNova AB, Stockholm, Sweden.
"It also normalized amphetamine-induced rotational behavior in 6-hydroxydopamine lesioned rats. Platelet-derived growth factor-BB promoted proliferation of neural progenitor cells in the subventricular zone.
"The effects on dopaminergic neurons and functional recovery could be blocked by co-infusion with a proliferation inhibitor, indicating a link between the proliferative and anti-parkinsonian effects. Based on the current data, we consider platelet-derived growth factor-BB a clinical candidate drug for treatment of Parkinson's disease," Haegerstrand added.
The new study was published in the inaugural issue of the Journal of Parkinson's Disease.